Be the first to know

Never miss an update from Exelixis. Did you know that during reporting season, the announcements from NASDAQ:EXEL often move the market?

Exelixis (NASDAQ:EXEL) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow EXEL

Exelixis (EXEL)

US NASDAQ:EXEL (5.7B)

18.45
-0.24 (-1.28%)
4:12pm EST
LOADING
Loading price chart..

Summary

Current Price: $18.45
52w High/Low: $15.02 - 25.31
Market Cap: 5.7B
Price/Earnings: 17.62
Dividend Yield: -
Volume/Average: 4.1M - 3.6M
Exelixis (NASDAQ:EXEL) Company Logo

Listed in 2000

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer... More
Exelixis (NASDAQ:EXEL) Company Logo

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.

Annual Reports

Exelixis (EXEL) 10-K Annual Report Feb 22nd 2019
2019
(1.2mb)
Exelixis (EXEL) 10-K Annual Report Feb 26th 2018
2018
(1.2mb)
Exelixis (EXEL) 10-K Annual Report Feb 27th 2017
2017
(1.0mb)
Exelixis (EXEL) 10-K Annual Report Feb 29th 2016
2016
(1.0mb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Implied Growth
53.8%
 
4.6%
 
 
Industry Avg
EXEL

ATTRACTIVE: Exelixis exhibits an implied growth ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. EXEL calculation: 10% - ($1.02 / $18.45) = 4.5% more
Price / Book
4.8
 
3.4
 
 
Industry Avg
EXEL

ATTRACTIVE: Exelixis exhibits a price/book ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Earnings
20.6
 
18.3
 
 
Industry Avg
EXEL

AVERAGE: Exelixis's price/earnings ratio of 18.3 is within a 15% range of the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Sales
21.6
 
6.1
 
 
Industry Avg
EXEL

ATTRACTIVE: Exelixis exhibits a price/sales ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. more

Company News

Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
February 11th, 2020 - Motley Fool

Cabozantinib may help delay the need for chemotherapy in advanced patients.

3 Stocks I'll Never Sell
February 7th, 2020 - Motley Fool

These businesses have proved they can stand the test of time.

3 Cancer Treatment Stocks to Buy Right Now
January 28th, 2020 - Motley Fool

These three companies are innovators in the development of cancer drugs, and they can also make you a lot of money.

Can Investors Excel in 2020 With Exelixis?
January 22nd, 2020 - Motley Fool

This pharma stock can look forward to a year with more readouts, potential approvals, and new clinical assets providing value in the oncology space.

5 Value Stocks That Will Make You Richer in 2020
January 9th, 2020 - Motley Fool

Bargains abound for patient long-term investors.

10 Top Stocks That Will Make You Richer in 2020
January 6th, 2020 - Motley Fool

Start the year off right by investing in these top-tier companies.

2 Incredibly Cheap Biotech Stocks
December 23rd, 2019 - Motley Fool

These promising stocks have been flying under the radar this year, but they're worth another look.

3 Top Growth Stocks to Buy in December
December 3rd, 2019 - Motley Fool

These three names could soar early in 2020.